PRIME THERAPEUTICS

Health Issues

PBM Transparency-issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. 117th Congress, H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022, Title VI, Section 602 Oversight of Pharmacy Benefit Managers, provisions relating to PBM audits and disclosures in the commercial market. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023, provisions related to the Federal Trade Commission regulation of PBMs. H.R. 1352, Increasing Access to Biosimilars, provisions related to expanding access to biosimilars. S. 113, Prescription Pricing for the People Act, provisions related to an FTC study of PBMs.

TargetedSENATE · HOUSE OF REPRESENTATIVES

Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022, P.L. 117-169 provisions on Medicare Part D modernization and drug price negotiation. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. CMS proposed rule (CMS-4201-P) Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly provisions related to the definition of Gross Covered Prescription Drug Costs.

SENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)